INVITRO SUSCEPTIBILITY OF MYCOBACTERIUM-KANSASII TO CLARITHROMYCIN

被引:14
作者
BIEHLE, J
CAVALIERI, SJ
机构
关键词
D O I
10.1128/AAC.36.9.2039
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The MICs of the macrolide clarithromycin for 31 clinical isolates of Mycobacterium kansasii were determined by three different methods. The methods employed were the proportion resistance method on 7H10 agar, the radiometric (BACTEC) method, and the T100 method of datum analysis. All methods gave similar results. The MICs were in a narrow range from 0.16 to 0.50-mu-g/ml, with the MICs for 90% of isolates tested of 0.50-mu-g/ml for the agar dilution and radiometric methods and 0.37-mu-g/ml for the T100 method. The MBCs were determined for nine representative isolates by the radiometric broth method. The MBCs were equal to the MICs for four isolates, and the MBCs were twofold higher than the MICs for five isolates. Killing of 99.9% of the bacterial population was achieved at a clarithromycin concentration of 2.0-mu-g/ml for all nine isolates tested.
引用
收藏
页码:2039 / 2041
页数:3
相关论文
共 21 条
[1]  
AHN CH, 1981, REV INFECT DIS, V3, P1028
[2]   COMPARATIVE INVITRO ACTIVITY OF THE NEW MACROLIDE A-56268 AGAINST MYCOBACTERIA [J].
BERLIN, OGW ;
YOUNG, LS ;
FLOYDREISING, SA ;
BRUCKNER, DA .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1987, 6 (04) :486-487
[3]   ACTIVITIES OF 4 MACROLIDES, INCLUDING CLARITHROMYCIN, AGAINST MYCOBACTERIUM-FORTUITUM, MYCOBACTERIUM-CHELONAE, AND M-CHELONAE-LIKE ORGANISMS [J].
BROWN, BA ;
WALLACE, RJ ;
ONYI, GO ;
DEROSAS, V ;
WALLACE, RJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :180-184
[4]  
CARPENTER JL, 1991, REV INFECT DIS, V13, P789
[5]   THE ACTIVITY OF CLARITHROMYCIN AND ITS 14-HYDROXY METABOLITE AGAINST HAEMOPHILUS-INFLUENZAE, DETERMINED BY INVITRO AND SERUM BACTERICIDAL TESTS [J].
DABERNAT, H ;
DELMAS, C ;
SEGUY, M ;
FOURTILLAN, JB ;
GIRAULT, J ;
LARENG, MB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :19-30
[6]   ACTIVITY OF CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM INFECTION IN PATIENTS WITH ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME - A CONTROLLED CLINICAL-TRIAL [J].
DAUTZENBERG, B ;
TRUFFOT, C ;
LEGRIS, S ;
MEYOHAS, MC ;
BERLIE, HC ;
MERCAT, A ;
CHEVRET, S ;
GROSSET, J .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (03) :564-569
[7]   INVITRO AND INVIVO ACTIVITIES OF CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM [J].
FERNANDES, PB ;
HARDY, DJ ;
MCDANIEL, D ;
HANSON, CW ;
SWANSON, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1531-1534
[8]   COMPARATIVE ANTIMYCOBACTERIAL ACTIVITIES OF DIFLOXACIN, TEMAFLOXACIN, ENOXACIN, PEFLOXACIN, REFERENCE FLUOROQUINOLONES, AND A NEW MACROLIDE, CLARITHROMYCIN [J].
GORZYNSKI, EA ;
GUTMAN, SI ;
ALLEN, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :591-592
[9]   CLARITHROMYCIN, A UNIQUE MACROLIDE - A PHARMACOKINETIC, MICROBIOLOGICAL, AND CLINICAL OVERVIEW [J].
HARDY, DJ ;
GUAY, DRP ;
JONES, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1992, 15 (01) :39-53
[10]   ENHANCEMENT OF THE INVITRO AND INVIVO ACTIVITIES OF CLARITHROMYCIN AGAINST HAEMOPHILUS-INFLUENZAE BY 14-HYDROXY-CLARITHROMYCIN, ITS MAJOR METABOLITE IN HUMANS [J].
HARDY, DJ ;
SWANSON, RN ;
RODE, RA ;
MARSH, K ;
SHIPKOWITZ, NL ;
CLEMENT, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (07) :1407-1413